Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS12 | O14924 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 9/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | IARS1 | P41252 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534591 | 1.00 | RGS12 (0.34) | RGS12TSHRALDH1A1HTTDPP4 | |
| SCHEMBL2678789 | 0.85 | TSHR (0.38) | RGS12TSHRALDH1A1HTT | |
| SCHEMBL11420895 | 0.82 | TSHR (0.40) | RGS12TSHRALDH1A1HTTTDP1 | |
| SCHEMBL6250456 | 0.82 | TSHR (0.40) | RGS12TSHRALDH1A1HTTTDP1 | |
| SCHEMBL854904 | 0.75 | RGS12 (0.37) | RGS12TSHRALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2974813 | 0.74 | RGS12 (0.36) | RGS12TSHRALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL8891060 | 0.73 | DPP4 (0.34) | DPP4DPP8DPP9DPP7IARS1 | |
| SCHEMBL1332682 | 0.72 | TSHR (0.42) | RGS12TSHRALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL10530948 | 0.71 | LMNA (0.31) | — | |
| SCHEMBL11537769 | 0.70 | TSHR (0.47) | RGS12TSHRALDH1A1HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6830904-B2 | Producing single diastereomers of isoleucine in high stereochemical purity by converting (R)-2-methylbutyraldehyde to a diastereomeric mixture of D-isoleucine hydantoin and L-allo-isoleucine hydantoin (5S-((R)-1-methylpropyl)hydantoin) | BIOCATALYTICS, INC. | 2004-12-14 | — | — | US | claimed |
| US-6822116-B2 | CONVERTING L-ISOLEUCINE TO CORRESPONDING HYDANTOIN; CONTACTING HYDANTOIN WITH D-HYDANTOINASE TO STEREOSELECTIVELY HYDROLYZE ANY D-ALLO-ISOLEUCINE HYDANTOIN IN MIXTURE TO CORRESPONDING N-CARBAMOYL-D-ALLO-ISOLEUCINE AND DECARBAMOYLATING | BIOCATALYTICS, INC. | 2004-11-23 | — | — | US | claimed |
| US-20040048342-A1 | Methods for producing diastereomers of isoleucine | CODEXIS, INC. | 2004-03-11 | — | — | US | claimed |
| US-20030219879-A1 | Method for producing D-allo -isoleucine | CODEXIS, INC. | 2003-11-27 | — | — | US | claimed |
| US-6830904-B2 | Producing single diastereomers of isoleucine in high stereochemical purity by converting (R)-2-methylbutyraldehyde to a diastereomeric mixture of D-isoleucine hydantoin and L-allo-isoleucine hydantoin (5S-((R)-1-methylpropyl)hydantoin) | BIOCATALYTICS, INC. | 2004-12-14 | — | — | US | disclosed |
| US-6822116-B2 | CONVERTING L-ISOLEUCINE TO CORRESPONDING HYDANTOIN; CONTACTING HYDANTOIN WITH D-HYDANTOINASE TO STEREOSELECTIVELY HYDROLYZE ANY D-ALLO-ISOLEUCINE HYDANTOIN IN MIXTURE TO CORRESPONDING N-CARBAMOYL-D-ALLO-ISOLEUCINE AND DECARBAMOYLATING | BIOCATALYTICS, INC. | 2004-11-23 | — | — | US | disclosed |
| US-20040048342-A1 | Methods for producing diastereomers of isoleucine | CODEXIS, INC. | 2004-03-11 | — | — | US | disclosed |
| US-20030219879-A1 | Method for producing D-allo -isoleucine | CODEXIS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-4423175-A | AND ALKALINE EARTH, ZINC, OR TIN COMPOUND | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-12-27 | — | — | US | disclosed |
| US-4384059-A | ADDITIONALLY WITH ALKALINE EARTH METAL, ZINC AND ORGANO TIN COMPOUNDS | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219879-A1 | Method for producing D-allo -isoleucine | DAO, DNPEP, AADAT | RGS12 3524/4885TSHR 4387/4885ALDH1A1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.